Beyer, Jorg, Collette, Laurence ORCID: 0000-0003-2518-7281, Sauve, Nicolas, Daugaard, Gedske ORCID: 0000-0002-9618-9180, Feldman, Darren R., Tandstad, Torgrim, Tryakin, Alexey ORCID: 0000-0003-2245-214X, Stahl, Olof, Gonzalez-Billalabeitia, Enrique, De Giorgi, Ugo, Culine, Stephane, de Wit, Ronald, Hansen, Aaron R., Bebek, Marko, Terbuch, Angelika ORCID: 0000-0003-2918-1370, Albany, Costantine, Hentrich, Marcus, Gietema, Jourik A., Negaard, Helene, Huddart, Robert A., Lorch, Anja, Cafferty, Fay H., Heng, Daniel Y. C., Sweeney, Christopher J., Winquist, Eric, Chovanec, Michal, Fankhauser, Christian, Stark, Daniel, Grimison, Peter, Necchi, Andrea, Tran, Ben, Heidenreich, Axel, Shamash, Jonathan, Sternberg, Cora N., Vaughn, David J., Duran, Ignacio, Bokemeyer, Carsten, Patrikidou, Anna, Cathomas, Richard, Assele, Samson and Gillessen, Silke ORCID: 0000-0001-5746-6555 (2021). Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. J. Clin. Oncol., 39 (14). S. 1553 - 1569. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755

Full text not available from this repository.

Abstract

PURPOSE The classification of the International Germ-Cell Cancer Collaborative Group (IGCCCG) has been a major advance in the management of germ-cell tumors, but relies on data of only 660 patients with seminoma treated between 1975 and 1990. We re-evaluated this classification in a database from a large international consortium. MATERIALS AND METHODS Data on 2,451 men with metastatic seminoma treated with cisplatin- and etoposide-based first-line chemotherapy between 1990 and 2013 were collected from 30 institutions or collaborative groups in Australia, Europe, and North America. Clinical trial and registry data were included. Primary end points were progression-free survival (PFS) and overall survival (OS) calculated from day 1 of treatment. Variables at initial presentation were evaluated for their prognostic impact. Results were validated in an independent validation set of 764 additional patients. RESULTS Compared with the initial IGCCCG classification, in our modern series, 5-year PFS improved from 82% to 89% (95% CI, 87 to 90) and 5-year OS from 86% to 95% (95% CI, 94 to 96) in good prognosis, and from 67% to 79% (95% CI, 70 to 85) and 72% to 88% (95% CI, 80 to 93) in intermediate prognosis patients. Lactate dehydrogenase (LDH) proved to be an additional adverse prognostic factor. Good prognosis patients with LDH above 2.5x upper limit of normal had a 3-year PFS of 80% (95% CI, 75 to 84) and a 3-year OS of 92% (95% CI, 88 to 95) versus 92% (95% CI, 90 to 94) and 97% (95% CI, 96 to 98) in the group with lower LDH. CONCLUSION PFS and OS in metastatic seminoma significantly improved in our modern series compared with the original data. The original IGCCCG classification retains its relevance, but can be further refined by adding LDH at a cutoff of 2.5x upper limit of normal as an additional adverse prognostic factor.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Beyer, JorgUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Collette, LaurenceUNSPECIFIEDorcid.org/0000-0003-2518-7281UNSPECIFIED
Sauve, NicolasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Daugaard, GedskeUNSPECIFIEDorcid.org/0000-0002-9618-9180UNSPECIFIED
Feldman, Darren R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tandstad, TorgrimUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tryakin, AlexeyUNSPECIFIEDorcid.org/0000-0003-2245-214XUNSPECIFIED
Stahl, OlofUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gonzalez-Billalabeitia, EnriqueUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
De Giorgi, UgoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Culine, StephaneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
de Wit, RonaldUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hansen, Aaron R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bebek, MarkoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Terbuch, AngelikaUNSPECIFIEDorcid.org/0000-0003-2918-1370UNSPECIFIED
Albany, CostantineUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hentrich, MarcusUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gietema, Jourik A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Negaard, HeleneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Huddart, Robert A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lorch, AnjaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Cafferty, Fay H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Heng, Daniel Y. C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sweeney, Christopher J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Winquist, EricUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Chovanec, MichalUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fankhauser, ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stark, DanielUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Grimison, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Necchi, AndreaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tran, BenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Heidenreich, AxelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Shamash, JonathanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sternberg, Cora N.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Vaughn, David J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Duran, IgnacioUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bokemeyer, CarstenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Patrikidou, AnnaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Cathomas, RichardUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Assele, SamsonUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gillessen, SilkeUNSPECIFIEDorcid.org/0000-0001-5746-6555UNSPECIFIED
URN: urn:nbn:de:hbz:38-608206
DOI: 10.1200/JCO.20.03292
Journal or Publication Title: J. Clin. Oncol.
Volume: 39
Number: 14
Page Range: S. 1553 - 1569
Date: 2021
Publisher: LIPPINCOTT WILLIAMS & WILKINS
Place of Publication: PHILADELPHIA
ISSN: 1527-7755
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
GERM-CELL CANCER; CHEMOTHERAPY; CISPLATINMultiple languages
OncologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/60820

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item